380sek
0,0 %
Date:2024-04-24Time:17:29:00Latest report:Q4-2023List:First NorthTicker:COMBI
Market Cap:75 msekEnterprise Value:-26 msekNet Sales:5,54 msekEarnings:-35,7 msekEmployees:0ISIN:SE0016101935

Ratios

10-year key figure history for CombiGene turnover, profit, dividend, equity, PE and PB.

Pre
Pre

Stockprice

Price movement for CombiGene with index and moving average MA50 and MA200.

Stockprice:3,80
MA50:3,72
MA200:4,15
Price/MA200:-8,4 %
RSI (14):51,1
Price/MA50:2,2 %

Description

CombiGene AB is a gene therapy explorer based in Sweden. The company is engaged in developing new methods for the treatment of neurological diseases and for epileptic patients who cannot be helped by available medical treatments at present. The company develops gene therapies with the ambition to offer patients affected by severe life-changing diseases opportunities for a better life.

Biotechnology